)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
UCB (UCB) investor relations material
UCB H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary31 Jul, 2025
Executive summary
Achieved record-breaking first-half 2025 results with net sales up 26% to as high as €3.32 billion, driven by five key growth drivers and strong execution of patient value strategy, especially BIMZELX®.
BIMZELX® quadrupled sales to nearly €800 million, expanded to 50 countries, and treated over 82,000 patients, with significant market share gains in psoriasis and hidradenitis suppurativa.
Significant pipeline progress with positive results in multiple Phase 2 and 3 studies, including Parkinson's, atopic dermatitis, and rare epilepsies.
Expanded U.S. manufacturing footprint with up to $5 billion greenfield investment, supporting future growth and patient access.
Recognized for sustainability leadership, maintaining top sector rankings and advancing ESG commitments.
Financial highlights
Net sales reached up to €3,321 million, up 26% year-over-year, with robust contributions from BIMZELX®, FINTEPLA®, RYSTIGGO®, ZILBRYSQ®, EVENITY®, and BRIVIACT®.
Adjusted EBITDA rose 58% to €1,033 million, with margin up to 29.6% from 23.4% year-over-year.
Core EPS increased 69% to €3.53 per share.
Adjusted gross margin improved to 79%, driven by favorable product mix.
Operating expenses grew 15%, below net sales growth, reflecting operating leverage.
Outlook and guidance
Upgraded 2025 guidance: revenue expected to reach at least €7 billion, adjusted EBITDA margin at or above 30%, and core EPS at least €7.25 per share.
Continued strong momentum expected for key growth drivers, especially BIMZELX®, with stable pricing outside the U.S.
Anticipate ongoing price erosion for CIMZIA® and currency headwinds, but EBITDA is protected by hedging.
No material impact expected from potential U.S. tariffs in 2025 due to proactive inventory management.
Continued investments planned in global launches and R&D pipeline.
Explain the updated 2025 financial guidance.
Assess BIMZELX's performance across indications.
Discuss the progress of bepranemab in Alzheimer's.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next UCB earnings date
H2 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
UCB SA is a global biopharmaceutical company specializing in the discovery and development of innovative medicines and solutions for severe neurological and immunological disorders. The company's main areas of focus include treatments for conditions such as epilepsy, Parkinson's disease, and various immunological diseases. UCB operates through its biopharmaceutical segment, which develops, manufactures, and markets these therapies. The company is headquartered in Brussels, Belgium, and its shares are listed on the Euronext Brussels.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage